Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma

Omid Yassaie, Cyrus Chehroudi and Peter C. Black

Abstract: Non-muscle invasive bladder cancer (NMIBC) has traditionally been managed with transurethral resection followed by intravesical chemotherapy and/or bacillus Calmette–Guerin (BCG) in a risk-adapted manner. These tumors commonly recur and can progress potentially to lethal muscle invasive disease. A major unmet need in the field of NMIBC is bladder preserving therapy for recurrent high-grade NMIBC after adequate intravesical BCG therapy. The current gold standard treatment for these BCG-unresponsive patients is radical cystectomy, which is associated with considerable morbidity and mortality, particularly in older and frailer patients. It is therefore critical to provide alternative treatment options with acceptable oncological outcomes. In this review we explore novel bladder-sparing treatment options including combination intravesical therapy, enhanced instillation methods, immunotherapy, gene therapy, targeted therapy, photodynamic therapy and BCG variants across the spectrum of NMIBC disease states, ranging from low grade BCG-naive patients through to high-grade BCG-unresponsive NMIBC.

Keywords: BCG-unresponsive bladder cancer, immunotherapy, intravesical BCG, intravesical chemotherapy, non-muscle invasive bladder cancer, novel therapies

Introduction
Approximately 75% of urothelial bladder cancers are non-muscle invasive bladder cancer (NMIBC), making it critically important to develop novel means to optimize management in this patient subgroup. These tumors are typically managed by transurethral resection followed by adjuvant intravesical instillations to reduce the risk of recurrence and progression. Current treatment of NMIBC is based on stratification into low, intermediate and high-risk groups. Low-risk tumors are conventionally managed with single dose intravesical chemotherapy while high-risk tumors are managed with adjuvant intravesical bacillus Calmette–Guerin (BCG). Intermediate-risk tumors may be managed with either intravesical chemotherapy or BCG dependent on patient, disease and clinician factors.

BCG is the most effective intravesical agent in high-risk NMIBC. It acts primarily through immune-mediated cytotoxicity involving both the innate [e.g. natural killer (NK) cells and granulocytes] and the adaptive (e.g. CD4+ and CD8+ lymphocytes) effector cells. BCG itself is also believed to have a direct effect on tumor cells. Standard intravesical BCG is successful in 60–70% of patients with NMIBC. High-grade recurrence after BCG presents a clinical challenge, and the optimal treatment of these patients remains unclear. The guidelines recommend radical cystectomy in these patients, with disease-free rates exceeding 90%. Bladder-sparing alternatives are limited. Novel therapeutic options for patients who recur after BCG are critical in order to reduce the number of patients needing cystectomy with its associated morbidity, while maintaining acceptable oncological outcomes. Many patients are unfit for cystectomy, and others decline cystectomy. The need for novel therapies is accentuated by BCG shortages which may
impact supply in the future. In this review we will explore novel therapies for patients with NMIBC.

**Methods**

We performed a literature review using the search terms ‘novel’, ‘non muscle invasive bladder cancer’, ‘BCG unresponsive’ in Pubmed and Google Scholar. We used only English language papers published after 1990. A similar search with the above terms was undertaken on clinicaltrials.gov to identify ongoing trials with novel treatments. We focused on phase II/III trials. References from selected articles were also checked to ensure completeness.

In this narrative review we will explore novel therapies according to the disease state in which they are primarily being developed: BCG-naïve, BCG-exposed and BCG-unresponsive. Due to historical inconsistencies in definitions of BCG failure and adequate BCG therapy, most studies do not distinguish ‘BCG unresponsive’ from ‘BCG exposed’.

**NMIBC disease states**

NMIBC disease states are defined by tumor grade and stage as well as prior BCG therapy (Figure 1 and Table 1). Intermediate and high-risk tumors are considered separately. Patients who have never received intravesical BCG are considered ‘BCG-naïve’. The term ‘BCG-unresponsive’ has evolved to encompass high-risk patients in whom additional intravesical BCG therapy is unlikely to be effective.7 Between these two groups are the patients with ‘BCG-exposed’ or ‘BCG-experienced’ NMIBC, who have received some BCG, but do not meet specific criteria for BCG-unresponsive NMIBC.

BCG-unresponsive comprises both BCG-refractory and early BCG-relapsing patients.8 In both instances, patients must have received adequate BCG therapy, which is defined as induction plus one round of maintenance or a second round of induction for patients with recurrent Ta or carcinoma in situ (CIS) disease, or simply one round of induction for patients with recurrent T1 tumors. In BCG-refractory patients adequate BCG fails to clear the disease, whereas in BCG-relapsing patients, high-risk NMIBC recurs after initial response. An early relapse is defined as recurrence within 6 months of the last BCG dose for papillary (Ta/T1) NMIBC and within 12 months for CIS.9 BCG-exposed patients typically recur after BCG induction therapy alone, meaning that they have not received ‘adequate’ BCG to be considered unresponsive, or they have a late relapse. The timing of relapse has important prognostic implications; an early relapse has a similar outcome to BCG-refractory disease, but late relapses may respond to additional BCG10 and generally have a more favorable outcome.9,11 Similarly, patients with Ta or CIS disease after induction BCG alone can be treated with additional BCG.

The natural history of BCG-refractory disease that is not managed with timely cystectomy is
often progression to muscle-invasive cancer, metastasis, and even death. Historical data suggest that the risk of metastasis in patients with BCG failure reaches 50% after three additional cycles of BCG. The need for novel bladder preserving therapies is therefore particularly acute for these patients.

A thorough review of established treatment options for BCG-unresponsive patients is beyond the scope of this review. Bladder preserving options include intravesical valrubicin, which was found to have a recurrence-free survival rate of only 8% at 30 months, and BCG with interferon-alpha, which has now been withdrawn from the market. Single agent intravesical chemotherapy with gemcitabine, mitomycin or docetaxel remains an option, but with low rates of durable response. Trimodal therapy can also be considered for BCG-unresponsive T1 disease although studies have been limited primarily to BCG-naïve disease. None of these therapies have been adequately studied in well-designed trials using current disease state definitions. As a result, there is no clearly defined standard bladder preserving treatment option for patients with BCG-unresponsive high-risk NMIBC.

### Novel therapies for BCG-unresponsive high-risk NMIBC

Only the most recent clinical trials have clearly distinguished the BCG-unresponsive disease state, because this definition has only evolved in the past several years. Many prior trials enrolled heterogeneous patient populations that sometimes included both high-risk and intermediate-risk disease, and used various criteria for defining BCG failure. These will nonetheless be described here in the context of BCG-unresponsive high-risk NMIBC. This has become the focus of drug development for many stakeholders, as it is an area of great unmet need, and the path to US Food and Drug Administration (FDA) registration is clearest. The most recent trials have been single-armed trials in patients with BCG-unresponsive CIS. A summary of active phase II/III trials that have not yet reported results is provided in Table 2.

### Combination intravesical chemotherapy

Recent efforts have focused on examining combination intravesical regimens for recurrences after prior BCG, including gemcitabine/docetaxel and cabazitaxel/cisplatin/gemcitabine. A study of 45
### Enhanced intravesical chemotherapies

| Agent                  | Study          | Study design                        | Inclusion criteria       | Mechanism                                                                 | Primary outcomes               |
|------------------------|----------------|-------------------------------------|--------------------------|---------------------------------------------------------------------------|--------------------------------|
| Photodynamic therapy   | NCT03945162    | Phase II single-arm                 | BCG-unresponsive CIS     | Instillation of photosensitizer [TLD1433] followed by transurethral irradiation | CR rate                        |
| Immunotherapy          |                |                                     |                          |                                                                           |                                |
| Durvalumab             | NCT03317158    | Multi-arm phase I/II study comparing durvalumab +/- BCG +/- EBRT | BCG-exposed              | PDL-1 inhibitor                                                          | Phase I: Determine recommended combination doses Phase II: 6-month relapse-free survival (RFS) |
| NCT02901548            | Phase II single-arm open-label | BCG-unresponsive CIS | CR rate                  |                                                                            |                                |
| Pembrolizumab          | NCT02625961 (KEYNOTE-057) | Phase II single-arm open-label | BCG-unresponsive CIS or high grade papillary | PD-1 inhibitor                                                          | CR rate                        |
| Nivolumab +/− BMS-986205 | NCT03819256    | Phase II randomized open-label      | BCG-unresponsive CIS     | PD-1 inhibitor                                                          | CR rate                        |
| Recombinant intravesical therapies |                |                                     |                          |                                                                           |                                |
| CG0070                 | NCT04452591    | Phase III single-arm open-label     | BCG-unresponsive CIS or papillary | GM-CSF-expressing oncolytic virus                                         | CR rate                        |
| Other therapies        |                |                                     |                          |                                                                           |                                |
| TAR-200 +/− cetrelimab | NCT04640623    | Phase II open-label TAR-200 versus cetrelimab versus cetrelimab + TAR-200 | BCG-unresponsive CIS or papillary | PD-1 inhibitor [cetrelimab] + extended release intravesical gemcitabine [TAR-200] | CR rate                        |
| CG0070 + pembrolizumab | NCT04387461    | Phase II single-arm                 | BCG-unresponsive CIS     | GM-CSF-expressing oncolytic virus + PD-1 inhibitor                         | CR rate                        |
| Pembrolizumab + gemcitabine | NCT04164082 | Phase II single-arm                 | BCG-unresponsive CIS or papillary | PD-1 inhibitor + chemotherapy                                              | CR rate                        |
| EG-70                  | NCT04752722    | Phase II single-arm                 | BCG-unresponsive CIS     | Non-viral gene therapy                                                    | CR rate                        |
| Erdafitinib            | NCT04172675    | Phase II multi-arm randomized trial | BCG-unresponsive CIS or papillary tumor with FGFR alteration | Fibroblast growth factor receptor inhibitor                               | Recurrence-free survival       |

BCG, bacillus Calmette–Guerin; CIS, carcinoma in situ; CR, complete response; FGFR, fibroblast growth factor receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; NMIBC, non-muscle invasive bladder cancer.
patients with high-risk NMIBC (90% with prior BCG) treated with gemcitabine/docetaxel revealed 34% to be free of disease at 2 years. Response rates were higher in BCG-relapsing compared with BCG-refractory patients and 30% underwent cystectomy before the end of the study period. A more recent multi-institutional study retrospectively reviewed 276 patients with recurrent NMIBC after prior BCG, including BCG-intolerant, BCG-exposed and BCG-unresponsive (n = 105) patients. One and 2-year high-grade recurrence-free survival was 65% and 52%, respectively.22 This combination has become popular in North America.

Device-assisted intravesical chemotherapy

The efficacy of intravesical chemotherapy is limited by short dwell time in the bladder and inadequate penetration into bladder tumor tissue. Novel approaches use either electrical current or heat to enhance drug uptake into the urothelium. Electromotive mitomycin C (EMDA-MMC) uses a catheter electrode to run current through the bladder wall and improve the penetration of mitomycin. EMDA-MMC has been examined as a possible alternative for intermediate-risk disease and in combination with BCG for high-risk disease;23 however, few studies to date have reviewed it in the BCG-refractory space. A small prospective study of 26 BCG-refractory patients reported a 12-month high-grade disease-free survival of 72% for patients with papillary tumors, and 38% for those with CIS.13

Intravesical chemohyperthermia (CHT) can utilize external heating of the chemotherapeutic agent (combat bladder recirculation) or application of microwave energy to the bladder through a specialized catheter (Synergo) that heats the bladder wall to 41–44°C.24 The latter device was used in a prospective study of patients with high and intermediate-risk NMIBC, 81% of whom had received prior BCG, to treat with MMC or epirubicin. The 2-year recurrence-free survival was 47%.25 The HYMN randomized controlled trial (RCT) randomly assigned non-cystectomy candidates with high-grade recurrence after prior BCG to either intravesical CHT or institution standard salvage therapy.26 The authors reported no difference in the primary outcome of complete response (CR) rate in CIS patients at 3 months, although the disease-free survival was actually worse with CHT than in the control arm in this subgroup of patients [hazard ratio (HR) 2.06, 95% confidence interval (CI) 1.17–3.62, \(p=0.01\)]. There was a trend towards improved disease-free survival in patients with papillary tumors treated with CHT (HR 0.5, HR 0.50, 95% CI 0.22–1.17, \(p=0.11\)), but the difference did not meet statistical significance. The HYMN study is noteworthy for being one of the few RCTs in patients with recurrent tumors after prior BCG, but it has been criticized for the heterogeneity in the control group and inadequate statistical power to perform subgroup analyses.

Intravesical taxanes have been successfully incorporated into micelles and investigated as potential salvage agents for BCG-refractory NMIBC. These nanoparticles are believed to act as mucoadhesives, improving the attachment of cytotoxic agents to the urothelium, increasing dwell time, and enhancing drug uptake.27 A single-arm, phase II trial testing albumin-bound paclitaxel in 28 high-risk NMIBC patients with recurrence after BCG induction demonstrated recurrence-free survival of 18% and cancer-specific survival of 91% at a median follow-up of 41 months.28

TAR-200 is a novel intra-vesical drug delivery system composed of gemcitabine and osmotic minitablets with urea as an active osmotic agent. The drug is given by an inserter every 3 weeks for 6 months and 3-monthly thereafter. This provides a slow release of the gemcitabine during the 3 weeks that the tablets are in the bladder, increasing dwell time and exposure. A phase II trial is currently underway comparing TAR-200 and cetrelimab (PD-1 inhibitor) each alone and in combination in BCG-unresponsive patients (NCT04640623).

Immunotherapy

Inhibitors of programmed cell death protein (PD1) and PD1 ligand (PDL1), (collectively termed immune checkpoint inhibitors) were approved for the treatment of metastatic bladder cancer post-platinum and in cisplatin-ineligible patients by the FDA in 2017.29,30 These agents represent a major breakthrough in the treatment of patients with metastatic bladder cancer. These agents interrupt negative regulatory signals that suppress tumor cell killing by activated T cells, thereby stimulating anti-tumor immune responses.

Pembrolizumab was approved by the FDA in January 2020 for the treatment of BCG-unresponsive CIS in patients ineligible for radical
cystectomy. The KEYNOTE-057 trial reported a 3-month CR rate of 40.2% in 96 patients with BCG-unresponsive CIS treated with intravenous pembrolizumab every 3 weeks for up to 2 years.\(^{31}\) The median duration of response was 16 months, so that 19% of patients were free of high-grade recurrence at one year. Radical cystectomy was required in 37.5% of patients but up-staging to muscle-invasive bladder cancer was observed in less than 10% of patients.\(^{32}\) Pembrolizumab is the first agent approved by the FDA for BCG-unresponsive NMIBC since valrubicin. It marks a key milestone in the development of novel therapeutics for this disease.

SWOG S1605 is a similar single-arm phase II study investigating systemic atezolizumab in the same disease state. Results from this trial indicate a CR rate of 41.1% at 3 months, 27.0% at 6 months and 14% at 18 months in patients with CIS.\(^{33}\) Patients in this study underwent mandatory re-biopsy at 6 months, which was not required in KEYNOTE-057. In S1605 and KEYNOTE-057 the rate of grade 3–5 adverse events was 13–16%, including one treatment-related death in S1605.\(^{33}\)

Preliminary data on intravesical administration of the interleukin (IL)-15RaFc superagonist N-803 were presented at the 2021 Genitourinary Cancer Symposium in February 2021. This agent is a chimeric protein consisting of a mutated IL-15 fused to the alpha-subunit of the IL-15 receptor and the crystallizable fragment (Fc) domain of an antibody. IL-15 serves as a positive regular of NK and T-cell activation. The N-803 combination affords increased stability and stimulation of the IL-15 receptor. The QUILT study treated BCG-unresponsive CIS patients with combination intravesical BCG and N-803 according to the traditional SWOG protocol for induction and maintenance BCG. Re-induction was allowed after 3 months for persistent disease. The authors reported a 71% CR rate (at 3 or 6 months) that lasted a median 19.2 months. Furthermore, 88% of patients in the trial remained cystectomy free.

Atezolizumab and pembrolizumab have been tested in BCG-unresponsive papillary (Ta/T1) NMIBC. Those results have been reported only for atezolizumab, for which the event-free survival was 65% at 6 months and 47% at 18 months in the S1605 trial.\(^{33}\) The combination of intravesical chemotherapy (gemcitabine) with immune checkpoint inhibition (pembrolizumab) is being tested in the Alliance A031803 trial (NCT04164082) and the combination of immunotherapy with other novel agents represents a promising path towards better outcomes in BCG-unresponsive patients. Immunotherapy represents a potential paradigm change for the management of patients with NMIBC that would require close collaboration between urologists and medical oncologists.

**Gene therapy**

Gene therapy is one of the most active areas of translational research for bladder cancer, and three promising agents are in advanced stages of clinical development. Nadofaragene firadenovec is a replication-deficient adenovirus programmed to express interferon-alpha (IFN-\(\alpha\)). It is administered together with an incipient Syn3 to promote uptake of the virus into tumor tissue.\(^{34}\) A phase I trial demonstrated detectable levels of urinary IFN-\(\alpha\) and no significant toxicity. A subsequent phase II study randomly assigned 40 patients with BCG-unresponsive NMIBC to low and high-dose nadofaragene.\(^{35}\) Fourteen patients (35%) were free of high-grade recurrence at 12 months (50% for patients with papillary tumors and 30% for CIS). A phase III trial reported an overall CR rate of 59.6% at 3 months, which decreased to 30.5% at 12 months.\(^{36}\) The CR rate was more favorable for papillary disease compared with CIS at 3 months (72.9% and 53.4%, respectively) and 12 months (43.8% and 24.3%, respectively). All patients underwent a mandatory re-biopsy after 12 months, indicating that the endpoint has been defined more stringently here than in some of the other similar trials. While this enhances the rigor of the study, the FDA does not require it for drug approval, so its use in clinical trials remains at the discretion of the study team. Nadofaragene has a favorable toxicity profile, with 4% of patients experiencing grade 3 and no patients suffering grade 4–5 treatment-related adverse events.

CG0070 is a conditionally replicating oncolytic adenovirus that expresses granulocyte-monocyte colony-stimulating factor (GM-CSF).\(^{37}\) Viral replication and GM-CSF expression are directly and indirectly under the control of the E2F-1 promoter, which is active only in tumors with alterations in the retinoblastoma pathway. It is typically co-administered with a permeabilizing agent (0.1% dodecyl maltoside (DDM)) to allow it to penetrate the plasma membrane. CG0070 has been tested in a single-arm, phase II trial in patients with BCG-unresponsive CIS with/without papillary tumor.\(^{38}\)
The agent was administered weekly for a 6-week induction course, followed by maintenance dosing at 6, 12, and 18 months. The CR rate at 12 months in 61 patients was 30% (27% in CIS and 38% in pure Ta/T1). Ten patients underwent cystectomy, of whom six had muscle invasive bladder cancer. Most of the adverse events were related to lower urinary tract symptoms, flu-like symptoms, and fatigue. An additional study looking at combination therapy with CG007 and pembrolizumab for BCG-unresponsive CIS is currently recruiting (NCT04387461).

BC-819 is a plasmid encoding the diptheria toxin administered intravesically with polyethyleneimine, a cationic membrane permeabilizer. The plasmid encodes the diptheria toxin under the control of the H19 promoter sequence, an oncofetal transcription factor upregulated in urothelial carcinoma. A phase II marker lesion trial was conducted in patients with intermediate-risk disease only (no high-grade or CIS) who had recurrent or persistent disease after at least one course of any intravesical therapy. BC-819 eradicated one-third of all marker lesions and 40% of patients remained disease-free at 2 years. A trial testing BC-819 in BCG-unresponsive NMIBC has not yet launched and clinical development of this agent has been put on hold.

**Targeted therapy**

Oportuzumab monatox is a recombinant protein composed of humanized anti-EpCAM antibody fused to *Pseudomonas* exotoxin A. Binding of this fusion protein to cell surface EpCAM leads to internalization of the *Pseudomonas* exotoxin by receptor-mediated endocytosis, and the toxin causes arrest of protein synthesis. Tumor EpCAM positivity has been a consistent inclusion criterion for enrolment in clinical trials. In a phase II study with EpCAM-expressing CIS, most of which was BCG-refractory, 40% of patients obtained a CR and 16% remained disease-free after 18–25 months follow-up. Results from a single-arm, phase III FDA registration trial in patients with BCG-unresponsive NMIBC were reported in a company business report and at the Bladder Cancer Advocacy Network (BCAN) Think Tank 2021. Oportuzumab was instilled into the bladder two times per week for 6 weeks followed by weekly for 6 weeks and every 2 weeks for up to 2 years. The CR rate in CIS patients was 39% at 3 months and 15% at 12 months. The agent was well tolerated.

**Photodynamic therapy**

Photodynamic therapy (PDT) uses light energy to eradicate malignant urothelial cells. An intravesical photosensitizing agent is administered, followed by insertion of a fiber through the urethra into the bladder to transmit light from an external source. Early efforts with PDT failed due to local toxicity of non-specific photosensitizers. Next-generation photosensitizing agents investigated in bladder cancer include the porphyrin hexaminolevulinate and ruthenium-based TLD1433. These agents are preferentially taken up by malignant cells and form reactive oxygen species when activated by the appropriate wavelength of light. Bader et al. tested PDT with hexaminolevulinate in a small series of 17 patients with recurrent NMIBC. While the majority had high-grade disease, only 12 had prior BCG therapy, with no data on the adequacy or nature of recurrence. Twelve per cent of patients were tumor free at 21 months. A phase I study for TLD1433 has been completed and a larger phase II trial in the BCG-unresponsive setting is underway (NCT03945162).

**Novel therapies for BCG-exposed high-risk NMIBC**

Clinical trial activity has also accelerated in the past several years in the BCG-exposed disease state due, at least in part, to its clear delineation from BCG-unresponsive high-risk NMIBC. Furthermore, as the standard trial design in the BCG-unresponsive setting requires only a single-arm trial, drug efficacy can potentially be validated in comparative trials in patients with BCG-exposed NMIBC. This is happening, for example, with systemic immune checkpoint blockade (NCT04149574 and NCT03711032). The standard treatment for patients with BCG-exposed high-risk NMIBC is further intravesical BCG. The established trial design therefore randomly assigns patients to additional BCG versus BCG plus a novel therapy.

**Novel therapies for BCG-naïve NMIBC**

Intravesical BCG is the standard first-line therapy for both intermediate and high-risk NMIBC. Patients who have not yet received BCG are considered BCG-naïve. Drug development in this setting typically requires randomization to BCG versus BCG plus a novel therapy. Other trials compare novel strains of BCG with standard
BCG. A summary of active phase II/III trials which have not yet been reported is provided in Table 3.

**Intravesical chemoablation**

Mitomycin has been investigated for its ablative effect potentially to replace transurethral resection of bladder tumor (TURBT) in low-grade NMIBC. The CALIBER study was a phase II feasibility study which randomly assigned patients to four once-weekly mitomycin treatments versus TURBT. The CR rate at 3 months was 37.0% in the chemoablation and 80.8% in the surgical arm.49 The authors concluded that this concept was not worth pursuing in a larger phase III trial. However, investigators in Denmark have initiated the phase III DaBlaCa13 study (NCT03348969) that will test three instillations of mitomycin per week over 2 weeks before TURBT versus standard adjuvant mitomycin after TURBT in patients with recurrent high and low-grade Ta bladder tumors. Racioppi et al.50 used the same regimen as an alternative to TURBT for recurrences measuring <1 cm in intermediate-risk NMIBC and found a CR rate of 62% at 39 months. UGN-102 is a novel thermosensitive hydrogel formulation recently studied as an ablative agent as an alternative to TUBRT in low grade NMIBC with CR rates of 86–100% at 2–4 weeks post instillation.51 The phase II OPTIMA II trial, testing six weekly instillations of UGN-102 in 63 patients with low-grade Ta tumor, found a 65% CR at 3 months, and 72.5% of these patients maintained this CR for 12 months.52

**Fibroblast growth factor receptor inhibitor**

Fibroblast growth factor receptor (FGFR) is a family of four cell-surface tyrosine kinase receptors (FGFR1–4). Erdafitinib, an FGFR inhibitor is FDA approved for use in platinum-refractory locally advanced and metastatic urothelial cancer with specific FGFR2 and FGFR3 alterations. Low grade papillary NMIBC harbors FGFR3 mutations in up to 75% of tumors, with a rapid drop off in frequency to 15–20% in CIS, high-grade T1 and muscle-invasive tumors.53 These findings make FGFR a particularly attractive target in low grade NMIBC. A currently accruing phase II trial will evaluate 4–6 weeks of oral pemigatinib in low and intermediate-risk NMIBC patients prior to TURBT (NCT03914794). The primary endpoint is complete response identified at the time of TURBT. Another phase II trial is comparing erdafitinib with investigator’s choice intravesical chemotherapy in high-risk BCG-exposed or BCG-unresponsive NMIBC patients, whose tumors contain an FGFR alteration (NCT04172675). The most common side effect of this drug class is hyperphosphemia which required serum monitoring and sometimes dose reduction. Skin and nail complications are common, and the grade 3–4 treatment-related adverse event rate was 67% in metastatic bladder cancer trials, suggesting that tolerability in early stage disease will be challenging.54 An intravesically administered FGFR inhibitor would be ideal for these patients in order to reduce toxicity.

**BCG strains and priming strategy**

BCG, as a live organism grown in culture, has evolved over time in different laboratories to generate numerous genetic strains. It is conceivable that different strains could elicit different responses in patients, leading to variable efficacy and toxicity. A prospective randomized trial from Bern has sparked interest in this topic, as the investigators showed clearly superior outcomes using the Connaught strain compared with the TICE strain.55 In that trial, however, patients were treated with induction BCG only. Large retrospective studies have failed to confirm differences between strains and a systematic review by Boehm et al. found no differences between the Tokyo, TICE and Pasteur BCG strains with respect to recurrence rate.56–59 The SWOG phase III RCT S1602 completed accrual in 2021. It has compared the Tokyo-172 and TICE strains.60 In a third arm, the Tokyo-172 strain was tested with pre-treatment intradermal BCG vaccination. Mouse models have suggested that this type of priming with BCG improves the immune response to intravesical BCG. Clinical evidence suggests also that patients with prior BCG vaccination have better outcomes with BCG therapy.61

**Recombinant BCG**

BCG has been genetically modified to make recombinant forms with improved efficacy and reduced adverse effect profile. Most of these agents have been developed primarily to improve BCG in the context of vaccination for prevention of tuberculosis. However, the same modifications could potentially enhance its activity in NMIBC treatment. Recombinant BCG is a promising prospect in NMIBC management and clinical trials will help to establish its role in the future.
Table 3. Ongoing clinical trials in novel agents for BCG-naïve NMIBC (phase II or later).

| Immunotherapy          | Study                             | Study design                                                                 | Inclusion criteria                  | Mechanism              | Outcome                                      |
|------------------------|-----------------------------------|------------------------------------------------------------------------------|-------------------------------------|------------------------|---------------------------------------------|
| Tokyo 172              | NCT03091660 ([S1602])             | Phase III 3 arm RCT 1. BCG TICE 2. BCG Tokyo strain 3. BCG Tokyo strain with intradermal vaccination | High-grade Ta, T1, CIS             | As above               | Time to high-grade recurrence               |
| Pembrolizumab          | NCT03540463                       | Phase II single arm                                                          | High-grade T1                       | PD-1 inhibitor         | CR rate                                     |
| Pembrolizumab + BCG    | NCT03711032 ([KEYNOTE- 676])      | Phase III RCT BCG +/- pembrolizum                                            | 2 cohorts: BCG-naïve and BCG-unresponsive | PD-1 inhibitor         | CR rate                                     |
| Durvalumab             | NCT03528694                       | Phase III RCT BCG +/- durvalum                                              | High-risk NMIBC                     | PD-L1 inhibitor        | CR rate                                     |
| N-803                  | NCT02138734                       | Phase Ib/lb BCG +/− ALT-803                                                  | High-risk NMIBC                     | IL-15 Superagonist     | CR rate                                     |
| Sasanlimab             | NCT04165317 ([CREST])             | Phase III 3 arm RCT 1 sasanlimab + BCG induction/maintenance 2 sasanlimab + BCG induction only 3 BCG induction/maintenance | High-risk NMIBC                     | PD-1 inhibitor         | CR rate                                     |
| Recombinant BCG        | VPM1002BC                          | Phase II RCT recombinant BCG: VPM1002 versus BCG post TURBT                    | NMIBC                               | Urease C replaced with listeriolysin from *Listeria monocytogenes* | Response rate |
| Cytotoxic therapy      | Mitomycin                          | Phase III RCT mitomycin 3× weekly for 2 weeks versus TURBT + adjuvant mitomycin | Ta NMIBC                            | CR within 2 years      |                                             |
|                        | Mitomycin                          | Phase II RCT 4-weekly mitomycin versus TURBT + adjuvant mitomycin             | Ta NMIBC                            | CR at 3 months         |                                             |
|                        | Liposomal paclitaxel                | Phase I/Ila single arm                                                        | Ta NMIBC                            | Paclitaxel incorporated into micelles | Safety                                      |
|                        | Neoadjuvant mitomycin              | Phase II neoadjuvant mitomycin versus placebo                                | NMIBC                               | Recurrence-free survival |                                             |
|                        | Hyaluronate + mitomycin            | Phase II RCT mitomycin +/- hyaluronate                                       | Low-risk NMIBC                      | Glycosaminoglycan       |                                             |

(continued)
VPM1002 is a recombinant BCG in which the urease C gene has been replaced by the listeriolysin encoding gene from *Listeria monocytogenes*. This modifies the phagosome membrane, increasing the release of antigen into the cytosol, which in turn promotes antigen presentation and T-cell response. This enhances phagocytosis and the inflammatory reaction. A phase I study demonstrated the safety of this agent and a phase II (NCT023714470) study is now underway.

Other recombinant BCG strains are still in pre-clinical testing. rBCG-S1P expresses a detoxified S1 subunit of pertussis. This recombinant form exhibits a stronger T-cell response to pertussis in mice and an improved anti-tumor effect in a murine orthotopic bladder cancer model. *In vitro* studies using human white blood cells demonstrated an enhanced inflammatory response to rBCG-S1P compared with wild type BCG. The anti-tumor effect was also improved *in vitro*.

Cho *et al.* have developed a BCG with resistance to anti-microbial peptides. Bladder cancer cells treated *in vitro* with this recombinant BCG demonstrated higher internalization and increased release of anti-tumor cytokines.

### Virus-based therapy

Oncolytic viruses are also being tested in the BCG-naïve setting. These are not only capable of replicating and destroying tumor cells, but also inducing a host tumoricidal immune response. Coxsackie virus is an enterovirus which is being investigated in phase I and phase II trials. After internalization of the virus by Intercellular Adhesion Molecule 1 (ICAM-1) receptors on bladder cancer cells, the virus can directly lyse the cells and induce an immune reaction which can potentially provide lasting protective immunity in the bladder. This response may be enhanced when combined with mitomycin.

### Immunotherapy

The response rates to immune checkpoint inhibition have been modest in patients with BCG-unresponsive high-risk NMIBC. Multiple prospective randomized phase II trials are assessing whether first-line combination of BCG with immune checkpoint inhibition can improve the response rate and the durability of response over induction and maintenance BCG alone. Furthermore, these trials are testing whether the addition of immune checkpoint blockade can
make maintenance BCG therapy unnecessary, so that patients require only induction BCG, thereby potentially limiting the local bladder toxicity, albeit at the expense of an increased risk of systemic toxicity.

Conclusions
A clear definition of NMIBC disease states has led to a resurgence of clinical trial activity in NMIBC, with numerous novel agents under study across the disease spectrum. Many recent clinical trials have focused on BCG-unresponsive high-risk NMIBC in which the unmet need is greatest and the path towards FDA registration most established, but novel therapies are also migrating into earlier disease states. One key paradigm shift has been the introduction of systemic therapy for NMIBC. Nonetheless, BCG remains the most effective agent in our armamentarium, more than 40 years after its introduction. Time will tell if ongoing combination trials can enhance the efficacy of BCG and alter the current first and second-line treatment algorithms.

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Peter C. Black https://orcid.org/0000-0002-2919-7068

References
1. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234–241.
2. Babjuk M, Burger M, Compérat EM, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta/T1 and Carcinoma In Situ) – 2019 update. Eur Urol 2019; 76: 639–657.
3. Sylvester RJ, Van Der Meijden AP, Witjes JA, et al. Bacillus Calmette–Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174: 86–91.
4. Redelman-Sidi G, Glickman MS and Bochner BH. The mechanism of action of BCG therapy for bladder cancer – a current perspective. Nat Rev Urol 2014; 11: 153–162.
5. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006; 49: 790–797.
6. Haas CR, Barlow LJ, Badalato GM, et al. The timing of radical cystectomy for bacillus Calmette–Guerin failure: comparison of outcomes and risk factors for prognosis. J Urol 2016; 195: 1704–1709.
7. Lerner SP, Dinney C, Kamat A, et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer 2015; 1: 29–30.
8. Shirakawa H, Kikuchi E, Tanaka N, et al. Prognostic significance of bacillus Calmette–Guerin failure classification in non-muscle-invasive bladder cancer. BJU Int 2012; 110: E216–E221.
9. Steinberg RL, Thomas LJ, Mott SL, et al. Bacillus Calmette–Guerin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease. Bl Cancer 2016; 2: 215–224.
10. Bretton PR, Herr HW, Kimmer ML, et al. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette–Guerin. J Urol 1990; 143: 710–712.
11. Herr HW, Milan TN, and Dalbagni G. BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol 2015; 33: 108.e1–108.e4.
12. Lerner SP, Tangen CM, Sucharew H, et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2009; 27: 155–159.
13. Racioppi M, Di Gianfrancesco L, Ragonese M, et al. ElectroMotive Drug Administration (EMDA) of mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer 2018; 18: 1224.
14. Steinberg G, Bahnsen R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette–Guerin refractory carcinoma in situ of the bladder. J Urol 2000; 163: 761–767.
15. Dinney CPN, Greenberg RE and Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette–Guérin. *Urol Oncol* 2013; 31: 1635–1642.

16. Bartoletti R, Cai T, Gacci M, *et al.* Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. *Urology* 2005; 66: 726–731.

17. Barlow LJ, McKiernan JM and Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette–Guérin therapy. *J Urol* 2013; 189: 834–839.

18. Weiss C, Wolze C, Engehausen DG, *et al.* Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? *J Clin Oncol* 2006; 24: 2318–2324.

19. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologies for treatment guidance for industry [Internet]. [https://www.fda.gov/media/101468/download](https://www.fda.gov/media/101468/download) (accessed 1 April 2021).

20. Decastro GJ, Sui W, Pak JS, *et al.* A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette–Guérin unresponsive or recurrent/recalping urothelial carcinoma of the bladder. *J Urol* 2020; 204: 247–253.

21. Steinberg RL, Thomas LJ, O’Donnell MA, *et al.* Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. *Bl Cancer* 2015; 1: 65–72.

22. Steinberg RL, Thomas LJ, Brooks N, *et al.* Multi-institutional evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. *J Urol* 2020; 203: 902–909.

23. Di Stasi SM, Giannantoni A, Giurioli A, *et al.* Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet Oncol* 2006; 7: 43–51.

24. Lammers RJ, Witjes JA, Imman BA, *et al.* The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. *Eur Urol* 2011; 60: 81–93.

25. Arends TJ, Van Der Heijden AG and Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. *J Urol* 2014; 192: 708–713.

26. Tan WS, Panchal A, Buckley L, *et al.* Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette–Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette–Guérin therapy (HYMN): a phase III, open-label, randomised controlled trial. *Eur Urol* 2019; 75: 63–71.

27. Mugabe C, Hadaschik BA, Kainthan RK, *et al.* Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. *BJU Int* 2009; 103: 978–986.

28. Robins DJ, Sui W, Matulay JT, *et al.* Long-term outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus Calmette–Guérin therapy. *Urology* 2017; 103: 149–153.

29. Bellmunt J, de Wit R, Vaughn DJ, *et al.* Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *N Engl J Med* 2017; 376: 1015–1026.

30. Vuky J, Balar AV, Castellano D, *et al.* Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. *J Clin Oncol* 2020; 38: 2658–2666.

31. Balar AV, Kulkarni GS, Uchio EM, *et al.* Keynote 057: phase II trial of Pembrolizumab (pembro) for patients (pts) with High-Risk (HR) Nonmuscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette–Guérin (BCG). *J Clin Oncol* 2019; 37 (Suppl. 7): 350.

32. Balar AV, Kamat AM, Kulkarni GS, *et al.* Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. *Lancet Oncol* 2021; 22: 919–930.

33. Black PC, Tangen C, Singh P, *et al.* Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). *J Clin Oncol* 2021; 39 (Suppl. 15): 4541.

34. Narayan VM and Dinney CPN. Intravesical gene therapy. *Urol Clin North Am* 2020; 47: 93–101.

35. Shore ND, Boorjian SA, Canter DJ, *et al.* Intravesical rAd–IFNa/Syn3 for patients with
high-grade, bacillus Calmette–Guerin-refractory or relapsed non–muscle-invasive bladder cancer: a phase II randomized study. *J Clin Oncol* 2017; 35: 3410–3416.

36. Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene fradenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. *Lancet Oncol* 2021; 22: 107–117.

37. Ramesh N, Ge Y, Ennist DL, et al. CG0070, A conditionally replicating granulocyte macrophage colony-stimulating factor – armed oncolytic adenovirus for the treatment of bladder cancer. *Clin Cancer Res* 2006; 12: 305–313.

38. Packiam VT, Lamm DL, Barocas DA, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. *Urol Oncol* 2018; 36: 440–447.

39. Packiam VT, Barocas DA, Chamie K, et al. LBA24 CG0070, An oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC): 12 month interim results from a multicenter phase II trial. *J Urol* 2018; 199: e1166.

40. Amit D and Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. *J Transl Med* 2010; 8: 134.

41. Gofrit ON, Benjamin S, Halachmi S, et al. DNA based therapy with diphtheria toxin-a BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. *J Urol* 2014; 191: 1697–1702.

42. Premsukh A, Lavoie JM, Cizeau J, et al. Development of a GMP phase III purification process for VB4-845, an immunotoxin expressed in E. coli using high cell density fermentation. *Protein Expr Purif* 2011; 78: 27–37.

43. Brunner A, Prelog M, Verdorfer I, et al. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. *J Clin Pathol* 2008; 61: 307–310.

44. Kowalski M, Guindon J, Brazas L, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette–Guérin. *J Urol* 2012; 188: 1712–1718.

45. Clark E. Sesen bio reports fourth quarter and full-year 2018 financial results and additional preliminary data from phase 3 VISTA trial [Internet]. https://ir.sesenbio.com/news-releases/news-release-details/sesen-bio-reports-fourth-quarter-and-full-year-2018-financial (2019, accessed 1 April 2021).

46. Nsyeo UO, Shumaker B, Klein EA, et al. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. *J Urol* 1998; 160: 39–44.

47. Karges J, Kuang S, Maschietto F, et al. Rationally designed ruthenium complexes for 1- and 2-photon photodynamic therapy. *Nat Commun* 2020; 11: 3262.

48. Bader MJ, Stepp H, Beyer W, et al. Photodynamic therapy of bladder cancer – a phase I study using Hexaminolevulinate (HAL). *Urol Oncol* 2013; 31: 1178–1183.

49. Mostafid AH, Porta N, Cresswell J, et al. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. *BJU Int* 2020; 125: 817–826.

50. Racioppi M, Di Gianfrancesco L, Ragonesi M, et al. Chemoablation with intensive intravesical mitomycin C treatment: a new approach for non-muscle-invasive bladder cancer. *Eur Urol Oncol* 2019; 2: 576–583.

51. Lenis A, Chamie K, Friedman B, et al. PD19-10 The chemoablative effect of vesigel instillation in patients with NMIBC – response rate and 1-year durability. *J Urol* 2017; 197: e368–e369.

52. Huang W, Chevli K, Trainer A, et al. Chemoablation with intensive intravesical mitomycin C treatment: an open-label multicenter phase II clinical trial. *J Urol* 2017; 198: e1115.

53. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. *Am J Pathol* 2001;158: 1955–1959.

54. Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial cancer. *N Engl J Med* 2019; 381: 338–348.

55. Rentsch CA, Birkhäuser FD, Biot C, et al. Bacillus Calmette–Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. *Eur Urol* 2014; 66: 677–688.

56. Krajewski W, Matuszewski M, Poletalajew S, et al. Are there differences in toxicity and efficacy between various bacillus Calmette–Guérin strains in bladder cancer patients? Analysis of 844 patients. *Urol Int* 2018; 101: 277–284.
57. Witjes JA, Dalbagni G, Karnes RJ, et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. *Urol Oncol* 2016; 34: 484.e19–484.e25.

58. Steinberg RL, Brooks NA, Thomas LJ, et al. Bacillus Calmette–Guérin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer. *Urol Oncol* 2017; 35: 201–207.

59. Boehm BE, Cornell JE, Wang H, et al. Efficacy of bacillus Calmette–Guérin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. *J Urol* 2017; 198: 503–510.

60. Svatek RS, Tangen C, Delacroix S, et al. Background and update for S1602 “a phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle-invasive bladder cancer”. *Eur Urol Focus* 2018; 4: 522–524.

61. Biot C, Rentsch CA, Gsponer JR, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. *Sci Transl Med* 2012; 4: 137ra72.

62. Kanno AI, Goulart C, Leite LCC, et al. A bivalent recombinant mycobacterium bovis BCG expressing the S1 subunit of the pertussis toxin induces a polyfunctional CD4 + T cell immune response. *Biomed Res Int* 2019; 2019: 9630793.

63. Rodriguez D, Goulart C, Pagliarone AC, et al. In vitro evidence of human immune responsiveness shows the improved potential of a recombinant BCG strain for bladder cancer treatment. *Front Immunol* 2019; 10: 1460.

64. Cho MJ, Kim MJ, Kim K, et al. The immunotherapeutic effects of recombinant bacillus Calmette–Guérin resistant to antimicrobial peptides on bladder cancer cells. *Biochem Biophys Res Commun* 2019; 509: 167–174.

65. Annels NE, Mansfield D, Arif M, et al. Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. *Clin Cancer Res* 2019; 25: 5818–5831.